Skip to main content
SpringerLink
Log in

Quelles stratégies dans le traitement des tumeurs neuroendocrines digestives ?

Treatment strategy of digestive neuroendocrine tumours

  • Review Article
  • Synthèse
  • Published:
Oncologie

Abstract

The management of digestive neuroendocrine tumours is a complex challenge because of very different clinical situations and several therapeutic options. The treatment of hormonal hypersecretion is the priority. Antitumoral treatment should be discussed during a specialized multidisciplinary board meeting.

Résumé

La prise en charge des tumeurs neuroendocrines digestives est un challenge parfois complexe compte tenu de la diversité des présentations cliniques et des nombreuses options thérapeutiques disponibles. Le contrôle d’un syndrome fonctionnel est la priorité. Le traitement antitumoral devra être décidé dans le cadre d’une concertation multidisciplinaire spécialisée.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Aparicio T, Ducreux M, Baudin E, et al. (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37: 1014–1019

    Article  CAS  PubMed  Google Scholar 

  2. Bajetta E, Rimassa L, Carnaghi C, et al. (1998) 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83: 372–378

    Article  CAS  PubMed  Google Scholar 

  3. Brixi-Benmansour H, Jouve JL, Mitry E, et al. (2011) Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Dig Liver Dis 43: 912–916

    Article  CAS  PubMed  Google Scholar 

  4. Cassier PA, Walter T, Eymard B, et al. (2009) Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 115: 3392–3399

    Article  CAS  PubMed  Google Scholar 

  5. Dahan L, Bonnetain F, Rougier P, et al. (2009) Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 16: 1351–1361

    Article  CAS  PubMed  Google Scholar 

  6. de Baere T, Deschamps F, Teriitheau C, et al. (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicineluting beads: preliminary results. J Vasc Interv Radiol 19: 855–861

    Article  PubMed  Google Scholar 

  7. Delaunoit T, Ducreux M, Boige V, et al. (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40: 515–520

    Article  CAS  PubMed  Google Scholar 

  8. Elias D, Goere D, Leroux G, et al. (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35: 1092–1097

    Article  CAS  PubMed  Google Scholar 

  9. Elias D, Lasser P, Ducreux M, et al. (2003) Liver resection (and associated extrahepatic resections) for metastatic welldifferentiated endocrine tumors: a 15-year single center prospective study. Surgery 133: 375–382

    Article  PubMed  Google Scholar 

  10. Engstrom PF, Lavin PT, Moertel CG, et al. (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol: official journal of the American Society of Clinical Oncology 2: 1255–1259

    CAS  Google Scholar 

  11. Faiss S, Pape UF, Bohmig M, et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689–2696

    Article  CAS  PubMed  Google Scholar 

  12. Imhof A, Brunner P, Marincek N, et al. (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90YDOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29: 2416–2423

    Article  CAS  PubMed  Google Scholar 

  13. Jensen RT, Cadiot G, Brandi ML, et al. (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95: 98–119

    Article  CAS  PubMed  Google Scholar 

  14. Kianmanesh R, O’Toole D, Sauvanet A, et al. (2005) Traitement chirurgical des tumeurs endocrines gastroenteropancréatiques. Part 1. Traitement de la tumeur primitive. J Chir (Paris) 142: 132–149

    Article  CAS  Google Scholar 

  15. Kianmanesh R, Sauvanet A, Hentic O, et al. (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247: 659–665

    Article  PubMed  Google Scholar 

  16. Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360: 195–197

    Article  CAS  PubMed  Google Scholar 

  17. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90: 220–226

    Article  CAS  PubMed  Google Scholar 

  18. Le Treut YP, Gregoire E, Belghiti J, et al. (2008) Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 8: 1205–1213

    Article  PubMed  Google Scholar 

  19. Marrache F, Vullierme MP, Roy C, et al. (2007) Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96: 49–55

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Mitry E, Baudin E, Ducreux M, et al. (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351–1355

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. O’Toole D, Ruszniewski P (2005) Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 19: 585–594

    Article  PubMed  Google Scholar 

  22. Oberg K (1996) Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours. Digestion 57(Suppl 1): 81–83

    PubMed  Google Scholar 

  23. Öberg K, Knigge U, Kwekkeboom D, et al. (2012) Neuroendocrine gastro-enteropancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7): vii124–vii130

    PubMed  Google Scholar 

  24. Rinke A, Muller HH, Schade-Brittinger C, et al. (2009) Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report From the PROMID Study Group. J Clin Oncol 27:4756–4763

    Article  Google Scholar 

  25. Salazar R, Wiedenmann B, Rindi G, et al. (2012) ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology 95: 71–73

    Article  CAS  PubMed  Google Scholar 

  26. Saltz L, Kemeny N, Schwartz G, et al. (1994) A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74: 958–961

    Article  CAS  PubMed  Google Scholar 

  27. Strosberg JR, Fine RL, Choi J, et al. (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117: 268–275

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Curie, 35, rue Dailly, F-92210, Saint-Cloud, France

    E. Mitry

  2. UFR des sciences de la santé, université Versailles, Saint-Quentin, France

    E. Mitry

Authors
  1. E. Mitry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Mitry.

About this article

Cite this article

Mitry, E. Quelles stratégies dans le traitement des tumeurs neuroendocrines digestives ?. Oncologie 15, 529–532 (2013). https://doi.org/10.1007/s10269-013-2331-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-013-2331-5

Keywords

Mots clés

Search

Navigation